We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Ultra-Portable Device Enables Finger-Prick Blood Testing at Home

By LabMedica International staff writers
Posted on 07 Aug 2026

Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. More...

In the UK, millions of tests are performed each year to diagnose disease, guide therapy, and track health, yet results usually capture a single moment. Home-based, longitudinal testing could highlight small physiologic changes and reduce travel for vulnerable groups such as people on chemotherapy.

King’s College London spinout Algocyte has introduced the Algocyte PROXIMA Mobile Health Station (MHS), an ultra‑portable blood testing device designed and manufactured in the UK. The instrument is intended for use by non‑specialist providers, including nurses, general practitioners, pharmacists, and care‑home staff. It uses a small finger‑prick sample and connects over Bluetooth to deliver results that can be shared with clinicians and patients on the spot, building a longitudinal picture of health.

The system combines two independent sensing technologies with a physics‑informed artificial intelligence (AI) approach. Its hybrid architecture integrates complementary deep‑learning models, including convolutional neural networks and Vision Transformers, and uses a quantum‑inspired aggregation inference method. By incorporating measurement redundancy and cross‑validating multiple sensing modalities, the device enables measurement of 12 biomarkers that comprise a Full Blood Count (FBC). It can operate via a mobile phone, run from a compact external power bank, and has been tested across Ethernet, Wi‑Fi, 5G, and 4G hotspots. According to the company, applications include conditions such as anemia, infection, inflammation, and cancer.

The device has achieved the UKCA mark as a UK in vitro diagnostics (IVD) General Class instrument and is progressing through further testing and evaluation in commercial deployment while gathering additional scientific evidence and completing further regulatory steps. The Algocyte PROXIMA MHS was launched on June 29 at the Royal Society of Medicine in London, where live demonstrations were accompanied by an immersive virtual‑reality training platform that simulates the complete workflow on Apple Vision Pro. The company reports ongoing pilots in early stages in the UK, Canada, and the United Arab Emirates, including feedback from National Health Service laboratorists and evaluation in a Canadian government rural community hub.

“This achievement demonstrates how academia and industry can work together to deliver meaningful social impact. Academia advances fundamental research into health, disease, and the application of AI to cell and molecular biology. Industry translates these advances into scalable technologies. This technology could have a real‑world impact on the many patients receiving treatments that would benefit from regular blood monitoring, such as chemotherapy or the use of medicines like clozapine, which require close monitoring of blood cell levels due to potential side effects or complications,” said Dr. Hector Zenil, founder and CEO of Algocyte, and Associate Professor in Healthcare Engineering at King’s College London.

Related Links
Algocyte


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.